Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05428319
Collaborator
(none)
70
1
28
2.5

Study Details

Study Description

Brief Summary

Prostatic carcinoma is the second most common cancer in men with high incidence of morbidity and mortality. It is a common health problem. Most cases occur at the age of 50 years, reaching its peak at 60-70 years of age. Diagnosis of prostatic carcinoma is still a problematic issue as accurate diagnosis can be very challenging due to the presence of either a small focus of cancer or the presence of many benign mimickers of malignancy.

Six transmembrane epithelial antigen of the prostate 1 (STEAP-1) is primarily localized at the cell membrane, mostly at cell-cell junctions, but it may also be found dispersed in the cytoplasm. In prostate, the expression of STEAP-1 is higher in neoplastic tissues compared to its restricted expression in normal prostatic samples.

The antibody designated as p40 recognizes exclusively ΔNp63 and not TAp63. In prostate tissues, it has been shown that p40, the ΔNp63 isoform of p63, stains prostatic basal cells as reliable as p63 in most cases. Furthermore, aberrant staining of tumor cells was seen more rarely with p40 than with p63.

In this study, we hope to solve some problematic issues in diagnosis of prostatic carcinoma and reach the better way to distinguish prostatic carcinoma from mimicking lesions by using both STEAP-1 and p 40. Also, the way to detect cancer at early stage of development and its progression which is extremely important as it allows establishing the most effective treatment and predicting patient's outcome.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    70 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers: An Immunohistochemical Study
    Anticipated Study Start Date :
    Aug 1, 2022
    Anticipated Primary Completion Date :
    Aug 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Diagnosis of Prostatic Carcinoma [One or two days after staining sections with the markers]

      Immunohistochemical Expression of STEAP-1 and p40 in Prostatic carcinoma and mimickers

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Male
    Inclusion Criteria:
    • Trans-rectal ultrasound guided biopsy (TRUS) procedure, transurethral resection prostatectomy (TURP) and radical prostatectomy.

    • Prostatic adenocarcinoma and prostatic lesions that mimic prostatic adenocarcinoma

    Exclusion Criteria:
    • Patients with recurrence of the primary tumor.

    • Patients with a history of preoperative chemotherapy and/or radiotherapy.

    • Insufficient or tiny tissue biopsies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Aliaa Bakr Ahmed Sohag Egypt 201

    Sponsors and Collaborators

    • Sohag University

    Investigators

    • Principal Investigator: Aliaa Bakr, Faculty of medicine, Sohag University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Aliaa Bakr Ahmed, Assistant lecturer, Sohag University
    ClinicalTrials.gov Identifier:
    NCT05428319
    Other Study ID Numbers:
    • Soh-Med-22-06-14
    First Posted:
    Jun 23, 2022
    Last Update Posted:
    Jun 23, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 23, 2022